• MALAYSIAN PSYCHIATRIC ASSOCIATION, Committee Member, 2002, (National)
• INTERNATIONAL EARLY PSYCHOSIS ASSOCIATION, Member, 2002, (International)
• MALAYSIAN MENTAL HEALTH ASSOCIATION, Member, 2003, (National)
• INTERNATIONAL HARM REDUCTION ASSOCIATION, Member, 2003, (International)
• PACIFIC RIM COLLEGE OF PSYCHIATRY, Member, 2004, (International)
• ASIAN HARM REDUCTION NETWORK, Member, 2004, (International)
• MALAYSIAN REACH CONSULTATIVE BOARD, Committee Member, 2004, (National)
• NATIONAL CREDENTIALING COMMITTEE & SPECIALTY SUBCOMITTEES ? COLLEGE OF PHYSICIANS, ACADEMY OF MEDICINE OF MALAYSIA, Committee Member, 2004, (National)
• ASIAN NETWORK OF EARLY PSYCHOSIS, Committee Member, 2005, (International)
• CAST Committee of Affective Disorders and Schizophrenia Training, Committee Member, 2007, (National)
• Malaysian DePain Board, Vice President, 2007, (National)
• Psychiatrty Conjoint Board, Board Member, 2011, (National)
• WORLD PSYCHIATRIC ASSOCIATION - Section on Urban Mental Health, Board Member, 2015 to 2020, (International)
• World Psychiatric Association Section on Urban Mental Health, Committee, 2015, (International)
• World Psychiatric Association Section on Urban Mental Health , Committee Members, 2015 to 2020, (International)
• World Psychiatric Association Section on Urban Mental Health, Active Member, 2018 to 2022, (International)

---

• Anti - bully committee, Faculty, 01/07/2018 to 30/06/2019
• Acting Head of Department, Faculty, 01/01/2018 to 31/07/2018
• Acting Head of Department, Faculty, 21/09/2015 to 24/09/2015 (MEMANGKU)
• Acting Head of Department, University Malaya, 06/07/2015 to 12/07/2015
• Acting Head of Department, University Malaya, 12/06/2015
• Acting Head of Department, Faculty, 31/03/2015 to 05/04/2015
• Acting Head of Department, Faculty, 26/11/2014 to 31/12/2014
• Acting Head of Department, Faculty, 21/10/2014 to 24/10/2014
• Acting Head of Department, Faculty, 04/06/2012 to 08/06/2012
• Ahli Jawatankuasa Ijazah Tingggi Fakulti Perubatan (JKITFP), Faculty, 01/07/2011
• Departmental Medical Reports - Moderator, Faculty, 01/06/2010
• Secretary- Psychiatry Interuniversity Conjoint Board (Jawatankuasa Bersama Sarjana Perubatan: Psikiatri), National, 01/07/2009
• Pengurus Psikofarmakologi, Faculty, 01/04/2008
• Submitting and vetting Masters in Psychological Medicine Part 1 and 2 Exams questions (Conjoint UM-UKM-USM), University Malaya, 31/03/2008
• Examiner for Final MBBS examinations, Faculty, 10/03/2008
• Submitting questions and vetting committee for OSCE and Problem solving for Final MBBS Exams , Faculty, 01/02/2008
• Committee Member of Technical Evaluation of Audiovisual Aids for Teaching, Exams and Research in Dept of Psychological Medicine, Faculty, 01/01/2005 to 31/12/2006
• Head and Coordinator of Early Intervention in Psychosis Programm, Faculty, 01/06/2004

---

• Psychiatry (Urban Mental Health)
• Psychiatry (Early Psychosis)
• Psychiatry (Psychosexuality)

---

Book

Article in Academic Journals

Proceeding

Mass Media(Newspaper,Radio,Tv,Popular Magazine)

List of Written Works That Have Not Been Published

Other Media(Tape,Video,Internet)

• Elucidating The Interaction Between Blastocystis sp. And Microbial Diversity To Study Its Effect On Healthy Individuals And Patients With Different Stages Of Colorectal Cancer, Consultant, 2019 - 2021, Skim Geran Penyelidikan Trans-Displin (TRGS), (National)
  
• Confirmatory Study of Dsp-5423p in Patients With Schizophrenia, Principal Investigator(PI), 2016 - 2018, Private Funding, (International)
  
• A multicentric multi country cross sectional study in Asian population to assess and describe cognitive dysfunction in MDD Lundbeck, 2015, Co-Investigator, 2015 - 2015, Private Funding, (International)
  
• A Phase Ii Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate The Efficacy, Safety and Tolerability of Four Orally Administrated Dose of Bi 409306 During a 12-Week Treatment Period in Patients With Schizophrenia On Stable Antipsychotic Treatment, Co-Investigator, 2015 - 2017, Private Funding, (International)
  
• Elevate. A Randomized, Double-Blind, Placebo- Controlled, Confirmatory Study Lurasidone Hcl in AdolescenceWith Schizophrenia, Co-Investigator, 2015 - 2018, Private Funding, (International)
  
• A Phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety and tolerability of four orally administered doses of BI 409306 during a 12 week treatment period in Patients with schizophrenia on stable antipsychotic treatment, Co-Investigator, 2015 - 2016, Private Funding, (International)
  
• Confirmatory Study of DSP-5423P in Patients with Schizophrenia (Phase III), Co-Investigator, 2015 - 2018, Private Funding, (International)
  
• A phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety and tolerability of four orally administrated dose of BI 409306 during a 12-week treatment period in patients with schizophrenia on stable antipsychotic treatment, Co-Investigator, 2015 - 2016, Private Funding, (International)
  
• Randomized, Double-Blind, Parallel-Group, Placebo- Controlled, Confirmatory Study of Sm-13496 (Lurasidone Hcl) in Patients With Schizophrenia (Phase Iii), Co-Investigator, 2015 - 2016, Private Funding, (International)
  
• A 104 week flexible dose, open label, multicenter, extension study to evaluate the long term safety and effectiveness of lurasidone in peadiatrics subjects, Principal Investigator(PI), 2015 - 2017, Private Funding, (International)
  
• Efficacy and safety of Tianeptine oral administration in elderly patients suffering from MDD, Co-Investigator, 2014 - 2015, Private Funding, (International)
  
• A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression (Phase III), Co-Investigator, 2014 - 2016, Private Funding, (International)
  
• A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Sm-13496 For The Treatment of Bipolar I Depression (Phase III, Co-Investigator, 2014 - 2016, International Funding, (International)
  
• Randomized, Double-blind, Parallel-group, Placebo- controlled, Confirmatory Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia (Phase III), Co-Investigator, 2013 - 2014, Private Funding, (International)
  
• Efficacy and safety of agomelatine (25 mg/day with blinded potential adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomized, double-blind, versus venlafaxine XR (75 mg/day with blinded potential adjustment up to 225 mg/day), 2-arm parallel groups, international multicenter study (Phase III), Co-Investigator, 2013 - 2013, Private Funding, (International)
  
• A Phase 2, Randomized, Double-blind, Placebo- controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Phase II), Co-Investigator, 2012 - 2013, Private Funding, (International)
  
• Sexual Dysfunction In Women With Major Depressive Disorder On Selective- Serotonin And Noradrenaline Re-uptake Inhibitors (snri), Principal Investigator(PI), 2012 - 2015, Geran Penyelidikan Universiti Malaya (UMRG Programme) - HTM (Wellness), (University)
  
• Sexual Dysfunction In Women With Major Depressive Disorder On Selective- Serotonin And Noradrenaline Re-uptake Inhibitors (snri), Principal Investigator(PI), 2012 - 2015, Geran Penyelidikan Universiti Malaya (UMRG), (National)
  
• Protocol R092670SCH3009 Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects with Schizophrenia When Switching from Oral Antipsychotics, Principal Investigator(PI), 2010 - 2012, International Funding, (International)
  
• A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 in patients with major depressive disorder Lundbeck A/SNov 2008 Jan 2010, Co-Investigator, 2010 - 2012, Lundbeck A/S, (International)
  
• A prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of Dapoxetine in men with Premature Ejaculation and concomitant Erectile Dysfunction treated with a Phosephodietterase-5 Inhibitor, Co-Investigator, 2010 - 2011, Janssen -Cilag, (International)
  
• A phase 3 randomized, placebo-controlled clinical trial to study the safety and efficacy of 3 doses of Lurasidone HCL in acutely psychotic patients with schizophrenia, Co-Investigator, 2009 - 2011, Dainippon Sumitomo, (International)
  
• Depression in Patients with epilepsy, Principal Investigator(PI), 2009 - 2009, Short Term Research Fund (Vote F)(PJP), (National)
  
• Sexual Satisfaction Among married Woman, Principal Investigator(PI), 2009 - 2012, Fundamental Research Grant Scheme (FRGS), (National)
  
• A randomized, double-blind, placebo and active controlled, parallel-group study to evaluate the efficacy and safety of 3 fixed doses of JNJ-37822681 administered twice daily in subjects with schizophrenia, Co-Investigator, 2009 - 2010, Johnson & Johnson, (International)
  
• SEXSUAL SATISFACTION AMONG MARRIED WOMAN, Principal Investigator(PI), 2009 - 2011, Geran Penyelidikan Universiti Malaya (UMRG), (International)
  
• An open label prospective trial to explore the tolerability, safety, and efficacy of flexibly dosed Paliperidone ER in Subjects with schizophrenia R076477-SCH-3022, Others, 2008 - 2008, Jansen Cilag, (National)
  
• Randomized, double blind, parallel group, placebo-controlled, duloxetine referenced dose finding study of LuAA24530 in Major Depression., Others, 2008 - 2008, lUNDBECK, (International)
  
• Depression in Epeliptic Patients in UMMC, Principal Investigator(PI), 2008 - 2009, UM, (University)
  
• Depression in Patients with Epilepsy, Principal Investigator(PI), 2008 - 2009, Short Term Research Fund (Vote F)(PJP), (National)
  
• Evaluation of Disability and Functioning amongst Patients With Depression Using International Classification of Functioning, Disability and Health (ICF) Core Sets, Co-Investigator, 2007 - 2008, W.H.O. Collaboration Project , (International)
  
• Depression and Functional Level in Chronic Hospitalized Schizophrenia Patients Compared to Community Care., Co-Investigator, 2006 - 2006, , (National)
  
• Psychiatric Posting in Final Year Medical Students: Do Attitudes Change, Co-Investigator, 2006 - 2006, NIL, (University)
  
• A Double Blind Randomized, Multicenter, Fixed-dosed Study Comparing the Efficacy of Escitalopram (20mg/day) versus Citalopram (40mg/day) in Patients with Major Depressive Disorder (10796) (Sponsor/Grant from Lundbeck), Co-Investigator, 2005 - 2006, Lundbeck, (International)
  
• A Pharmacoeconomic Study Conducted in Parallel With Clinical Trial 10199, A Randomized, Double Blind, Flexible Dose Study Evaluating the Efficacy and Safety of 6 Months Treatment With Bifeprunox or Risperidone In Patients With Schizophrenia (10224) and A Pharmacoeconomic Study Conducted in Parallel With Clinical Trial 10200, A 6 Months Double Blind, Risperidone Referenced, Flexible Dose, Parallel-Group, Extension Study of Bifeprunox In Patients With Schizophrenia (10225) - Co Investigator (Sponsor/Grant from ), Co-Investigator, 2005 - 2006, Lundbeck, (International)
  
• An Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration of Quetiapine Fumarate in the treatment of Bipolar I Manic Episode, Co-Investigator, 2005 - 2005, Astra Zeneca International Research and development, (University)
  
• Recurrent Status Pseudoepilepticus- An Analysis of cases, Co-Investigator, 2005 - 2005, , (University)
  
• An Open Label Prospective Study to Assess the Efficacy, Safety and Tolerability of 36 weeks Lamotrigine in the Prevention of Mood Episodes in subjects with Bipolar Disorder, who are in Remission, Following a Manic / Hypomanic Index Episode or a Depressive Index Episode (SCA101469), Co-Investigator, 2005 - 2006, GlaxoSmithKline, (International)
  
• Prodromal Symptoms and Duration Of Untreated Illness., Principal Investigator(PI), 2004 - 2004, , (University)
  
• Indications and Outcome of the Use of Quietiapine in University Malaya Medical Centre, Co-Investigator, 2004 - 2004, , (University)
  
• Methadone Hydrochloride Maintenance In Treatment Of Heroin Dependence, Principal Investigator(PI), 2004 - 2004, DuoPharma Biotech, (National)
  
• The Use of Physical Restraints in Elderly Medically Ill Inpatients, Co-Investigator, 2004 - 2004, , (University)
  
• Diabetes Mellitus, Obesity and Lipid Abnormalities in Schizophrenic Patients Treated with Atypical Antipsychotics., Co-Investigator, 2004 - 2004, Janssen Cilag, (National)
  
• Characteristics of patients seeking help through the IVRS System for early detection of mental illnesses, Principal Investigator(PI), 2003 - 2008, Lilly Malaysia Sdn Bhd, (National)
  
• Adolescent Psychiatric Disorders in The Inpatient Psychiatric Unit, Co-Investigator, 2003 - 2003, , (University)
  
• Substance Use Among Juvenile Delinquents At Sekolah Tunas Bakti, Kuala Lumpur, Co-Investigator, 2003 - 2003, , (National)
  
• Pattern of Use of Physical Restraints on Psychiatric Inpatients, Co-Investigator, 2003 - 2003, , (University)
  
• Characteristics of patients Presenting with First Episode Psychosis, Principal Investigator(PI), 2003 - 2004, UM, (University)
  
• HIV Risk Behaviours Among Intravenous Drug Users, Principal Investigator(PI), 2001 - 2002, , (National)
  
• Psychiatric Morbidity Among Drug Offenders in a Drug rehabilitation Centre, Principal Investigator(PI), 2001 - 2002, , (National)
  
• A Long Term Study About The Use Of Risperidone In Malaysia., Co-Investigator, 2000 - 2003, , (University)
  

---

• A long term sTudy of SM-13496 in Patients with Bipolar I Disorder, 2015-2015, Dainippon Sumitomo Pharma Japan
• Cofirmatory Study of DSP-5423P in Patients with Schizophrenia (Phase 3), 2015-2015, Sumitomo Dainipon Pharma Co. Japan
• A Phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety and tolerability of four orally administered doses of BI 409306 during a 12 week treatment period in Patients with schizophrenia on stable antipsychotic treatment, 2015-2015, Boehringer Ingelheim
• 3. A phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety and tolerability of four orally administrated dose of BI 409306 during a 12-week treatment period in patients with schizophrenia on stable antipsychotic treatment (Phase II) (Mar 2015 present) BI, 2015-2015, Boehringer Ingelheim
• A 104 week flexible dose, open label, multicenter, extension study to evaluate the long term safety and effectiveness of lurasidone in peadiatrics subjects, 2015-2015, Dainippon
• Efficacy and safety of Tianeptine oral administration in elderly patients suffering from MDD, 2014-2014, Servier, France
• A 6-week Randomized, Parallel, double blind, placebo controlled, fixed dose, multicenter study to evaluate the efficacy and safety of lurasidone in adolescent subjects with schizophrenia, 2014-2014, Sunovion Pharmaceuticals Inc, New Jersey, USA
• A Long-Term Study of SM-13496 in Patients with Bipolar I Disorder (Phase III), 2014-2014, Sumitomo Dainipon Pharma Co. Japan
• A Multicenter, randomized, Double blind trial to Assess the efficacy and safety of ASC-01 in patients with Major Depressive Disoreder, 2014-2014, Otsuka Pharmaceutical Co. Japan
• A phase 3, multicenter, extension study of Study ALK9072-003EXT2 to assess the long term safety and durability of effect of ALKS 9072 in subjects with stable schizophrenia, 2014-2014, Alkermes Inc, MA, USA
• A multicentric multi country cross sectional study in Asian population to assess and describe cognitive dysfunction in MDD, 2014-2014, Lundbeck
• A multicenter, active-controlled, double-blind parallel group-comparison trial to investigate the efficacy and safety of aripiprazole IM depot (OPC-14597IMD) compared with aripiprazole tablets in patients with schizophrenia, 2013-2013, Otsuka Pharmaceutical Co. Japan
• A Long Term, Phase 3, Multicenter, Open Label Trial to evaluate the safety and tolerability of oral OPC-34712 as maintenance treatment in Adults with schizophrenia, 2013-2013, Otsuka Pharmaceuticals Japan
• Efficacy and safety of agomelatine (25 mg/day with blinded potential adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomized, double-blind, versus venlafaxine XR (75 mg/day with blinded potential adjustment up to 225 mg/day), 2-arm parallel groups, international multicenter study (Phase III), 2013-2013, Servier, France
• Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects with Schizophrenia When Switching from Oral Antipsychotics, 2011-2011, jOHNSON AND jOHN SON
• ALPHA Study - Phase 3 Randomised Double Blind Trial of IM Depot Aripripazole VS Placebo, 2011-2011, Otsuka
• Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects with Schizophrenia When Switching from Oral Antipsychotics, 2011-2011, Otsuka
• Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects with Schizophrenia When Switching from Oral Antipsychotics, 2011-2011, jOHNSON AND jOHN SON
• ALBERIO: A multi-national, Multi Center, double blind, placebo-controlled, parallel group. Fixed dose efficacy and safety study of SR58611A 350 mg Twice daily vs. placebo in adults with Major Depressive Disorder on Concomitant Treatment with escitalopram, 2010, Sanofi Aventis Sdn Bhd
• A Randomized, Double blind, placebo and active-controlled, parallel group Study to evaluate the efficacy and safety of 3 fixed doses of JNJ-37822681 Administered Twice daily in subjects with schizophrenia, 2010-2010, Johnson and Johnson
• A Randomized, Double Blind, Flexible Dose Study Evaluating the Efficacy and Safety of 6 Months Treatment With Bifeprunox or Risperidone In Patients With Schizophrenia (10199) and A 6 Months Double Blind, Risperidone Referenced, Flexible Dose, Parallel-Group, Extension Study of Bifeprunox In Patients With Schizophrenia (10200), 2008-2008, -Lundbeck
• A 6-week Multicenter, International, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Queitiapine Fumarate Immediate Release Tablets in Daily doses of 400mg and 800mg Compared with Placebo in the Treatment of Adolescents with Schizophrenia (D1441C00112), 2007-2007, Astra Zeneca
• Protocol No.: 11613A; (A Double-Blind, Randomised, Parallel Group, Placebo-Controlled Study of the Safety, Tolerability and Efficacy following sequential dose regimens of Lu 31 -130 to MALE PATIENTS WITH Schizophrenia., 2006-2006, Lundbeck
• A 8-week Randomized, Double-Blind, Parallel Group, Phase III Study of the Efficacy and Safety of Agomelatine versus fluoxetine in outpatients with Major Depressive Disorder (CL3-20098-052), 2006-2006, Servier
• Protocol No.: 11492A; (Double-Blind, Randomised, Placebo-Controlled Study Comparing the Efficacy and Safety of Two Fixed Doses of a Novel Antidepressant Compound To That of Placebo in Patients With Major Depressive Disorder. - Co Investigator (Sponsor/Grant from ), 2006-2006, Lundbeck
• Protocol No.: 11613A; (A Double-Blind, Randomised, Parallel Group, Placebo-Controlled Study of the Safety, Tolerability and Efficacy following sequential dose regimens of Lu 31 -130 to MALE PATIENTS WITH Schizophrenia., 2006-2006, Lundbeck
• Protocol R076477-BIM-3004. A Randomized, Double Blind, Active and Placebo-Controlled, Study to Evaluate the efficacy and Safety Paliperidone ER as a Maintenance Treatment After an Acute Manic or Mixed Episode Associated with Bipolar I Disorder, 2005-2005, Jansssen-Cilag
• A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release OROS Paliperidone (3,9, and 15mg/day) and Olanzapine (10mg/day), With Open Label Extension, in the Treatment of Subjects With Schizophrenia, 2005-2005, Jansssen-Cilag
• A Multicenter, Double Blind, Randomized, Parallel-Group Active and Placebo-Controlled, Phase III Study to Evaluate the efficacy and Safety of Queitiapine Fumarate as Monotheraphy in the Treatment of Adult Patients with Major Depressive Disorder (D1446C00004), 2005-2005, Aztra Zeneca
• A Double Blind Randomized, Placebo-Controlled Relapse Prevention Trial with 10-20mg Escitalopram in Obsessive Compulsive Disorder (10193), 2005-2005, Lundbeck
• Multicenter Randomised Parallel Group, Double Blind, Placebo Controlled, Phase III Study of the Efficacy and Safety of Quietiapine Fumarate and lithium as monotherapy in 28-104 weeks treatment of Bipolar 1 Disorder in Adult Patients., 2005-2005, Quintiles East Asia
• Exploration of In Vitro/In Vivo Correlation of Paliperidone Palmitate Long Acting Formulation (Phase 1), 2005-2005, Jansssen-Cilag
• Efficacy of Monotheraphy Seroquel in Bipolar Depession EMBOLDEN, 2005-2005, Astra Zeneca
• An International, Multicenter, Large Simple Trial (LST) to Compare The Cardiovascular Safety of Ziprasidone and Olanzapine, 2005-2005, Pfizer
• A Randomized, Double Blind, Placebo Controlled Study to Explore the Efficacy and Safety of Risperidone Long Acting Intramuscular Injectables in the Prevention of Mood Episodes in Bipolar I Disorder, 2005-2005, Jansssen-Cilag
• A Randomized, Double Blind Trial, Placebo Controlled Study to Evaluate the Efficacy and Safety of Paliperidone Palmitate in Subjects with Schizophrenia, 2005-2005, Jansssen-Cilag
• A Placebo Controlled,Double Blind, Randomized, Parallel Group Study of the Efficacy and Safety of Dapoxetine in the treatment of Men with Premature Ejaculation, 2005-2005, Johnson and Johnson
• A Phase III Randomized, Placebo Controlled, Double Blind Trial, Evaluating the Efficacy and Safety of of Sublingual ASENAPINE vs Olanzapine and Placebo in In-Patients with an Acute Mania Episode, 2005-2005, Pfizer
• A Double Blind Randomized, Multicenter, Fixed-dosed Study Comparing the Efficacy of Escitalopram (20mg/day) versus Citalopram (40mg/day) in Patients with Major Depressive Disorder, 2005-2005, Lundbeck Asia
• A 12-Week, International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching Any Antipsychotic Treatment to Sustained-Release Quietiapine Fumarate (SEROQUEL) in Patients with Schizophrenia, 2005-2005, Quintiles East Asia
• Sertindole versus Risperidone Safety Outcome Study: A Randomised, Partially Blind, Parallel-Group, Active-Controlled, Post Marketing Study (SCoP 99824), 2004-2004, Lundbeck

---

• Certificate of Achievement Recruiting and Randomizing Firts Patient in Asia Pacific for Aspire I Study, Johnson and Johnson, 2017, (International)
• Sijil Penghargaan Penceramah Bengkel Pemantapan Calon Post Graduasi 2017, Pusat Perubatan Universiti Malaya, Kementerian Kesihatan Malaysia, 2017, (University)
• Certificate of Appreciation Organizer, Post Graduate Psychiatry Research Competition, Dept of Psychological Medicine, University Malaya, Malaysian Psychiatric Association, 2015, (University)
• Top Recruiter for Clinical Trials, Dept of Psychological Medicine, 2015, (Department)
• Certificate of Excellent Service, University Malaya, 2014, (University)
• Sijil Penghargaan Analisa Dan Pembentangan Hasil Kajian Premelinari Bagi Kertas Cadangan Rombakan Kurikulum, Jawatankuasa Pengajian Bersama Sarjana Kepakaran, 2013, (National)
• Anugerah Perkhidmatan Cemerlang, Unuversity Malaya, 2013, (University)
• Asian Researcher Travel Award, Otsuka Pharmaceutical Development Cooperation, Japan, 2012, (International)
• Honorary Fellow Philippine College of Neuropsychopharmacology, Philippine College of Neuropsychopharmacology, 2009, (International)
• Young Psychiatrist Travel Award from Japanese Society of Psychiatry and Neurolgoy, Japanese Society of Psychiatry and Neurology, 2008, (International)
• Certificate of Excellent Service, University Malaya, 2007, (University)
• Excellence Service Award, University Malaya, 2006, (University)
• Anugerah Perkhidmatan Cemerlang, Universiti Malaya, 2006, (University)
• Anugerah Perkhidmatan Cemerlang, University Malaya, 2005, (University)
• Certificate of Excellent Service, University Malaya, 2005, (University)
• Anugerah Perkhidmatan Cemerlang, University Malaya, 2004, (University)

---

---

• Projek Kurikulum Nasional Sarjana Perubatan Klinikal, Projek Kurikulum Nasional Sarjana Perubatan Klinikal, Committee Member, 2016-2020, (National)

---

• Asia-Pacific Journal of Clinical Oncology (Title: Prevalence of distress in cancer patients undergoing chemotherapy) ,  ( )
• Regular peer reviewer for Malaysian Journal of Psychiatry, Article In Journal ,  (2015)
• Reviewer for Malaysian Jpurnal of Psychiatry, Article In Journal ,  (2009)

---

• World Psychiatric Association section on Urban Mental Health Committee Member, (International), 01/01/2015 until 31/12/2017
• URUSETIA KURSUS BIMBANGAN UNTUK BAKAL CALON PROGRAM SARJANA PSIKIATRI KEMENTERIAN KESIHATAN, (Country), 26/11/2012 until  
• Organising Committee for the 5th BETA: Bipolar Educational Training for Asia Forum, Kuala Lumpur, (International), 06/07/2012 until 07/07/2012
• Penceramah Jemputan. Jabatan Psikiatri Hospital Kuala Pilah Bengkel Psikiatri , (District), 16/01/2012 until  
• Updates on Mood Disorders. Hospital Kuala Pilah Workshop on Psychiatric Updates for Paramedical Staff . 26th Sept 2011, (District), 26/09/2011 until 05/09/2011
• Ahli Jawatankuasa Rukun Tetangga, (Community), 01/06/2010 until  
• Organising Committee For International Society of Bipolar Disorders (Malaysian Chapter) Congress. Putrajaya, 13th 14th March 2010, (National), 13/03/2010 until 14/03/2010
• Penceramah Infopsikik (Musim Ke-dua). TV2. Mac 2009, (National), 03/03/2009 until 03/03/2009
• Organising committee for CINP Pacific-Asia Regional Meeting. 2 5 March 2008. Kuala Lumpur Convention Centre, (International), 02/03/2008 until 05/03/2008
• Organising committee (Secretary)for 13th Malaysian Conference on Psychological Medicine; 7th 9th June 2007, (Country), 07/06/2007 until 09/06/2007
• Speaker at Bahagian Perkhidmatan Farmasi, Jab Kesihatan Pahang, Mental Health Seminar for Pharmacists Management of Bipolar Disorder, Kuantan 20th September 2006., (District), 20/09/2006 until  
• Penceramah Jemputan - Updates in Medical Rehabilitation for Caregivers Depression in Stroke Patients . University of Malaya, Kuala Lumpur. 6th September 2006, (Community), 06/09/2006 until  
• Speaker at Schizophrenia Awareness Day :Violence in Schizophrenia and Relapse Prevention Malaysian Mental Health Foundation- Putra Hotel, Kuala Lumpur, 14th August 2006., (Country), 14/08/2006 until 14/08/2006
• Penceramah Jemputan - Persatuan Mencegah Dadah Malaysia (PEMADAM)- Kolokium:Memperkasa Institusi Keluarga Pusat Komuniti Sri Petaling. 11 September 2004, (Community), 11/09/2004 until  
• Malaysian Pharmaceutical Society Seminar on Management of Mental Disorders Early Intervention in Psychosis and Psychosocial Approach to Managing Mental Disorders Royal Adelphi Hotel, Seremban. 24th August 2004, (District), 24/08/2004 until  
• Penceramah Jemputan - Persekutuan Orang Pekak Malaysia Persidangan Keluarga Bekak Bahagia Trauma Ibubapa Apabila Mendapat Anak Pekak. Hotel Crown Princess, KL. 8TH August 2004., (Country), 08/08/2004 until  
• Penceramah Jemputan - Bengkel Pelan Tindakan Kesihatan Mental Negeri Kelantan Pengesanan Awal Masalah Kesihatan Mental Tumpat, Kelantan. 6th 8th April 2004, (District), 06/04/2004 until  
• Sukarelawan / Elektif - Pusat Serenti Rawang, December 2001, (Community), 01/12/2001 until 31/12/2001

---

• Schizophrenia Family Education Kit, Educational CDS, 01/06/2010, (NATIONAL)

---

POST GRADUATE STUDENT
(Name of Degree), (Name of Candidates), (Title of Thesis), (Academic Session)

FIRST DEGREE/DIPLOMA/PRE-DEGREE
(Course Title), (Academic Session), (No. of Candidates)

---